Helicoll®
Acellular dermal replacement for wound healing (e.g., diabetic foot ulcers)
ApprovedActive
Key Facts
Indication
Acellular dermal replacement for wound healing (e.g., diabetic foot ulcers)
Phase
Approved
Status
Active
Company
About Encoll
Encoll is a private, commercial-stage medical device and biomaterials company with a proprietary platform for producing ultra-pure, phosphorylated Type-I collagen. Its flagship product, Helicoll®, is an acellular dermal substitute approved for wound management and has secured an Innovative Technology contract with Vizient, Inc. The company leverages its patented Two-step enzyme Treatment Process (TTP) to serve multiple sectors, including surgical applications, biotechnology research, and skincare, positioning itself as a specialized supplier of bioactive collagen.
View full company profile